Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study.
Vidal N, Climent MÁ, Pérez S, Méndez-Vidal MJ, Anguera G, Martínez Salas I, Gallardo E, Cuéllar-Rivas MA, Molina-Cerrillo J, Martín A, Rodriguez-Vida A, Almagro Casado E, Gonzalez M, Domènech M, Martínez Kareaga M, Fernández Calvo O, Villa Guzmán JC, Vázquez Estévez S, González-Del-Alba A, Puente J. Vidal N, et al. Among authors: molina cerrillo j. Clin Transl Oncol. 2024 Oct 6. doi: 10.1007/s12094-024-03744-6. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39369361
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study.
Fiala O, Massari F, Basso U, Giannatempo P, Grande E, Buti S, Myint ZW, De Giorgi U, Pichler R, Grillone F, Ürün Y, Calabrò F, Bourlon MT, Galli L, Kanesvaran R, Roviello G, Kucharz J, Rizzo M, Park SH, Cerbone L, Seront E, Messina C, Molina-Cerrillo J, Santini D, Yano A, Incorvaia L, Catalano M, Pinto A, Formisano L, Soares A, Facchini G, Fornarini G, Poprach A, Rebuzzi SE, Nasso C, Spinelli GP, Angel M, Stellato M, Tural D, Aurilio G, Epstein I, Carrozza F, Monteiro FSM, Benedetti G, Büchler T, Ortega C, Zakopoulou R, Battelli N, Porta C, Bellmunt J, Gupta S, Santoni M. Fiala O, et al. Among authors: molina cerrillo j. Target Oncol. 2024 Nov;19(6):905-915. doi: 10.1007/s11523-024-01099-0. Epub 2024 Oct 1. Target Oncol. 2024. PMID: 39354179 Free PMC article.
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1).
Santini D, Li H, Roviello G, Park SH, Grande E, Kucharz J, Basso U, Fiala O, Monteiro FSM, Poprach A, Buti S, Molina-Cerrillo J, Catalano M, Buchler T, Seront E, Ansari J, Myint ZW, Ghosn M, Calabrò F, Kopp RM, Bhuva D, Bourlon MT, Roberto M, Di Civita MA, Mollica V, Marchetti A, Soares A, Battelli N, Ricci M, Kanesvaran R, Bamias A, Porta C, Massari F, Santoni M. Santini D, et al. Among authors: molina cerrillo j. Target Oncol. 2024 Nov;19(6):893-903. doi: 10.1007/s11523-024-01096-3. Epub 2024 Sep 17. Target Oncol. 2024. PMID: 39289313
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.
Choueiri TK, Albiges L, Barthélémy P, Iacovelli R, Emambux S, Molina-Cerrillo J, Garmezy B, Barata P, Basu A, Bourlon MT, Moon H, Ratta R, McKay RR, Chehrazi-Raffle A, Hammers H, Heng DYC, Braendle E, Beckermann KE, McGregor BA, Motzer RJ. Choueiri TK, et al. Among authors: molina cerrillo j. Lancet. 2024 Oct 5;404(10460):1309-1320. doi: 10.1016/S0140-6736(24)01758-6. Epub 2024 Sep 13. Lancet. 2024. PMID: 39284329 Clinical Trial.
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study).
Ciccarese C, Büttner T, Cerbone L, Zampiva I, Monteiro FSM, Basso U, Pichler M, Vitale MG, Fiala O, Roviello G, Kopp RM, Carrozza F, Pichler R, Grillone F, Calabuig EP, Zeppellini A, Küronya Z, Galli L, Facchini G, Sunela K, Mosca A, Molina-Cerrillo J, Spinelli GP, Ansari J, Scala A, Mollica V, Grande E, Buti S, Kanesvaran R, Zakopoulou R, Bamias A, Rizzo M, Massari F, Iacovelli R, Santoni M. Ciccarese C, et al. Among authors: molina cerrillo j. Int J Cancer. 2024 Dec 1;155(11):2036-2046. doi: 10.1002/ijc.35141. Epub 2024 Sep 7. Int J Cancer. 2024. PMID: 39243397
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project.
Rizzo A, Monteiro FSM, Ürün Y, Massari F, Park SH, Bourlon MT, Poprach A, Rizzo M, Takeshita H, Giannatempo P, Soares A, Roviello G, Molina-Cerrillo J, Carrozza F, Abahssain H, Messina C, Kopp RM, Pichler R, Formisano L, Tural D, Atzori F, Calabrò F, Kanesvaran R, Buti S, Santoni M. Rizzo A, et al. Among authors: molina cerrillo j. Target Oncol. 2024 Sep;19(5):747-755. doi: 10.1007/s11523-024-01089-2. Epub 2024 Aug 6. Target Oncol. 2024. PMID: 39107651
Transcriptomic Differences in Medullary Thyroid Carcinoma According to Grade.
Ruz-Caracuel I, Caniego-Casas T, Alonso-Gordoa T, Carretero-Barrio I, Ariño-Palao C, Santón A, Rosas M, Pian H, Molina-Cerrillo J, Luengo P, Palacios J. Ruz-Caracuel I, et al. Among authors: molina cerrillo j. Endocr Pathol. 2024 Sep;35(3):207-218. doi: 10.1007/s12022-024-09817-0. Epub 2024 Jul 3. Endocr Pathol. 2024. PMID: 38958823 Free PMC article.
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project.
Rizzo A, Buti S, Giannatempo P, Salah S, Molina-Cerrillo J, Massari F, Kopp RM, Fiala O, Galli L, Myint ZW, Tural D, Soares A, Pichler R, Mennitto A, Abahssain H, Calabrò F, Monteiro FSM, Albano A, Mollica V, Giudice GC, Takeshita H, Santoni M; ARON Working Group. Rizzo A, et al. Among authors: molina cerrillo j. Clin Exp Metastasis. 2024 Oct;41(5):655-665. doi: 10.1007/s10585-024-10296-0. Epub 2024 Jun 8. Clin Exp Metastasis. 2024. PMID: 38850317
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations.
Incorvaia L, Monteiro FSM, Massari F, Park SH, Roviello G, Fiala O, Myint ZW, Kucharz J, Molina-Cerrillo J, Santini D, Buttner T, Poprach A, Kopecky J, Zeppellini A, Pichler M, Buchler T, Pichler R, Facchini G, Fay AP, Soares A, Manneh R, Iezzi L, Kuronya Z, Russo A, Bourlon MT, Bhuva D, Ansari J, Kanesvaran R, Grande E, Buti S, Santoni M. Incorvaia L, et al. Among authors: molina cerrillo j. Cancer Immunol Immunother. 2024 Jun 4;73(8):142. doi: 10.1007/s00262-024-03719-0. Cancer Immunol Immunother. 2024. PMID: 38832989 Free PMC article.
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study).
Fiala O, Buti S, Bamias A, Massari F, Pichler R, Maruzzo M, Grande E, De Giorgi U, Molina-Cerrillo J, Seront E, Calabrò F, Myint ZW, Facchini G, Kopp RM, Berardi R, Kucharz J, Vitale MG, Pinto A, Formisano L, Büttner T, Messina C, Monteiro FSM, Battelli N, Kanesvaran R, Büchler T, Kopecký J, Santini D, Giudice GC, Porta C, Santoni M. Fiala O, et al. Among authors: molina cerrillo j. Target Oncol. 2024 Jul;19(4):587-599. doi: 10.1007/s11523-024-01065-w. Epub 2024 May 5. Target Oncol. 2024. PMID: 38704759 Free PMC article.
73 results